On December 20, 2019, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu®) for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
According to findings from a new analysis published in JAMA Oncology, multigene testing should be expanded to all women with breast cancer and not just those with certain family histories or clinical factors.
On December 18, 2019, the U.S. Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (PadcevTM) for adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
Participants in ONS’s Fourth Annual Capitol Hill Days quickly saw the fruits of their efforts when two ONS priority bills were passed in the U.S. House of Representatives in October 2019. The yearly advocacy, education, and training event, held September 22–24, brought 110 ONS activists to Washington, DC, for two days of sessions, briefings, updates, and meetings. The advocates engaged in 55 hours of intensive political and policy analysis, enabling them to take the Society’s health policy priority agenda to the U.S.
Bioengineers may have found a way to use tamoxifen activated with blue light to control precisely which tissues and body areas CAR T cells attack, reducing toxicities in other parts of the body. They reported their work in ACS Synthetic Biology.
On December 16, 2019, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi®) for patients with metastatic castration-sensitive prostate cancer.
Jamie is completing her last cycle of carboplatin and paclitaxel for stage I ovarian cancer. The oncology infusion nurse notices that Jamie appears withdrawn and nervous, so he takes time to ask her how she is feeling about completing treatment. Jamie responds, “I feel as frightened about finishing treatment as I did when I was diagnosed with cancer.” She also shares that she doesn’t want to ring the cancer center’s bell to ceremoniously signify the end of her treatment because she doesn’t want to “jinx it.”
The Elijah E. Cummings Lower Drug Costs Now Act of 2019, otherwise known as H.R. 3, is a top priority for House Speaker Nancy Pelosi (D-CA). But she’s facing challenges from progressive Democrats on her left more so than the conservative Senate on her right. Watering down provisions in H.R. 3 too much will lose her the votes she needs to pass the bill in the House, but passing a bill that’s too overarching or progressive will allow Senate Majority Leader Mitch McConnell (R-KY) to refuse to take up the legislation at all.
For more than 35 years, the Oncology Nursing Foundation has been devoted to supporting cancer nursing excellence. To steward those efforts in the years to come, the Foundation welcomes Anizia Karmazyn as its new executive director. Karmazyn will work with Foundation Board of Trustees, Linda Worrall, RN, MSN, the Foundation’s director of grants and program, and other Foundation staff to Increase support for oncology nursing education, research, and leadership development.